Today’ ’s Technology, Tomorrow s Technology, Tomorrow’ ’s Therapy s Therapy Today Disclaimer Disclaimer The material contained in this presentation must be considered as general background information on Cygenics Ltd. This s general background information on Cygenics Ltd. This The material contained in this presentation must be considered a presentation does not contain any earning guidance. The information presented is in summary form and where indicated presentation does not contain any earning guidance. The informat ion presented is in summary form and where indicated figures used are unaudited. The information contained in this presentation is subject to risks and uncertainties that may esentation is subject to risks and uncertainties that may figures used are unaudited. The information contained in this pr cause actual results to differ materially from those indicated. This information should not be relied upon or seen as advice This information should not be relied upon or seen as advice cause actual results to differ materially from those indicated. as to investors. Investors should obtain independent professiona as to investors. Investors should obtain independent professional advice. l advice.
Who we are Who we are CyGenics is a cell therapy company CyGenics is a cell therapy company focused on the development and focused on the development and commercialisation of adult stem cell commercialisation of adult stem cell related technologies related technologies
Value proposition Value proposition Technology + Revenue = Managed risk Technology + Revenue = Managed risk Near term clinical trial results Near term clinical trial results Rapidly growing revenue streams Rapidly growing revenue streams Strong and Global IP position Strong and Global IP position
The next medical milestone The next medical milestone 3 Milestones Expanded and/or in Medicine Differentiated Stem Cell Transplant 2 Primary Cell Transplant 1 Chemotherapy / Symptomatic Treatment Technology Progression
Cell Therapy market space Cell Therapy market space Clinical Therapy Value Add Diagnostics & Clinical Indications Biologics Theranostics Trials Tissue Products & Equipment & Support Reagents Banking Devices Instruments Services
Company structure & businesses Company structure & businesses Clinical Therapy Value Add Diagnostics & Clinical Indications Biologics Theranostics Trials Tissue Products & Equipment & Support Reagents Banking Devices Instruments Services
Revenue by business – – Tissue Banking Tissue Banking Revenue by business Cordlife Sign-up Revenue (A$000) $2,000 $1,500 $1,506 $1,000 $1,062 $893 $500 •Average revenue growth of •Average revenue growth of $257 $0 30% since FY’03 30% since FY’03 FY02 FY03 FY04 FY05 •Expansion in new markets to •Expansion in new markets to drive strong revenue growth drive strong revenue growth Cordlife Annuity Revenue (A$000) •Substantial increase in FY’06 $150 •Substantial increase in FY’06 annuity revenue annuity revenue $100 $95 $88 $50 $17 $0 $1 FY02 FY03 FY04 FY05
Revenue by business – – Products & Devices Products & Devices Revenue by business Cell Sciences Revenue (A$000) $1,000 $750 $500 $558 $250 $66 $0 FY04 FY05 •Strong revenue growth •Strong revenue growth •Expansion of product range •Expansion of product range to drive strong revenue to drive strong revenue growth growth
Revenue by business – – Support Services Support Services Revenue by business Cytomatrix Revenue (A$000) $2,000 •Current revenue from $1,500 •Current revenue from annual contracts annual contracts $1,230 $1,000 $1,124 •Revenue growth from •Revenue growth from other services other services $500 $0 FY04 FY05
Market size & growth Market size & growth USD$ mil 2002 2007 2012 USD$ mil 2002 2007 2012 Cord Blood Cord Blood $200 m $200 m $700 m $700 m $1.3 b $1.3 b banking banking Supporting Supporting $2.5 b $2.5 b $3.7 b $3.7 b $7.8 b $7.8 b technologies: cell technologies: cell lines, cell culture, lines, cell culture, delivery devices delivery devices Source : JainPharmaBiotech 2004 edition
Company structure & businesses Company structure & businesses Clinical Therapy Value Add Diagnostics & Clinical Indications Biologics Theranostics Trials Tissue Products & Equipment & Support Reagents Banking Devices Instruments Services
Commercialising Core Core Commercialising Technologies Technologies Stem Cell T cell Expansion Production Technology Technology
Stem Cell Expansion Stem Cell Expansion Problem • Insufficient stem cells for most adult transplants Answer • 3D scaffold for growth of adult stem cells -> expanded high quality stem cells Expansion
Stem Cell Expansion Market Stem Cell Expansion Market Worldwide (1 st World) market size Kit Price Kit Price US $10,000 US $10,000 Cancers of the I mmune Incidence in Developed Regions System (New Cases Annually) potential 358,000 potential 358,000 patients (1st world) patients (1st world) Leukaemia 124,202 Leukaemia 124,202 Multiple Myeloma 55,166 Multiple Myeloma 55,166 50,000 potential 50,000 potential Hodgkin’ ’s Lymphoma s Lymphoma 28,033 Hodgkin 28,033 kit sales annually kit sales annually Non- -Hodgkin Hodgkin’ ’s Lymphoma s Lymphoma 151,096 Non 151,096 Total 358,497 Total 358,497 Potential sales Potential sales $500m annually $500m annually Source: Data derived from GLOBOCAN 2002 database: summary table (abstracts), International Agency for Research on Cancer (IARC) and CANCERMondial, Descriptive Epidemiology Group (DEP) of IARC Expansion
T cell immunotherapy T cell immunotherapy What is a T Cell? What is a T Cell? Type of white blood cell that coordinates the immune system Type of white blood cell that coordinates the immune system Millions of T cells are made by our Thymus when young made by our Thymus when young Millions of T cells are Each T cell targets a specific disease, virus, cancer or bacteria ia Each T cell targets a specific disease, virus, cancer or bacter V β 1 V β 2 V β 3 V β 4 V β 5.1 V β 5.2-3 V β 6.1-3 360 360 360 360 400 360 360 T Cells
T cell immunotherapy T cell immunotherapy Problem • T cell generation by the Thymus is limited beyond puberty • Gaps in T cell repertoire occur due to: Aging Infections Treatments Answer • 3D scaffold technology creates artificial thymus • Stem cells + Stroma + Cytomatrix ™ � new T cells T Cells
Restoration of the human immune system T cell immunotherapy T cell immunotherapy T Cells
T Cell Immunotherapy Market T Cell Immunotherapy Market Worldwide (1 st World) market size Primary Primary Developed Regions Developed Regions Developed Regions Developed Regions Immunodeficiency (Incidence) (Prevalence) Immunodeficiency (Incidence) (Prevalence) Kit Price Kit Price US $10,000 US $10,000 Primary 51,000 2 million Primary 51,000 2 million Immunodeficiency Immunodeficiency 780,000 potential 780,000 potential Secondary Secondary Developed Regions Developed Regions Developed Regions Developed Regions st world) patients (1 st Immunodeficiency Immunodeficiency (New Cases Annually) (New Cases Annually) (Existing Carriers) (Existing Carriers) patients (1 world) Non- -HIV Severe HIV Severe 360,000 NA Non 360,000 NA 150,000 potential 150,000 potential Immunodeficiency Immunodeficiency kit sales annually kit sales annually Non- -HIV Viral HIV Viral 300,000 23.6 million Non 300,000 23.6 million Infection (HBV) Infection (HBV) Potential sales Potential sales HIV HIV 70,000 70,000 1.75- 1.75 -1.95 million 1.95 million US $1.5b annually US $1.5b annually Total Total 781,000 781,000 27.35 million 27.35 million Source: Data derived from GLOBOCAN 2002 database: summary table (abstracts), International Agency for Research on Cancer (IARC) and CANCERMondial, Descriptive Epidemiology Group (DEP) of IARC and various others T Cells
Cell therapy business model Cell therapy business model Therapy areas Clinical trial stages Direct sales HIV Hepatitis Leukaemia Production kits Stem cell transplants Phase I Phase II Phase III Revenue Pre-clinical (~10-20 patients) (~20-30 patients) (~100-150 patients) Prostate cancer Strategic Partners Breast cancer Melanoma Herpes Indirect Sales CMV EBV Blood disorders T Cells Expansion
Intellectual property Intellectual property • Exclusive & perpetual rights to matrix (non-orthopedic) • 4 patents issued � Stem cell matrix expansion � Stem cell collagen expansion � T cell production • 25 others pending � Stem cell expansion � T cell production � Spinner systems � Multi-potent stem cells
Company financials (for 30 Company financials th June 2005) (for 30 th June 2005) Consolidated revenue $4,122,000 Shares on issue 68,000,000 Net tangible assets at 18.4 cents/share $12,521,000 Cash $13,724,000 Cash burn (current) 1 $374,000 per month 1 Running rate (P&L account) refers to the average monthly loss from operations before depreciation of fixed assets and amortisation of goodwill, patents and licenses.
Recommend
More recommend
